{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-003243","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.305570+00:00","generated_at":"2026-06-15T02:29:09.183965+00:00","sec_items":["3.03","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Xenetic Biosciences announces 1-for-10 reverse stock split effective May 15, 2023","bullets":["Reverse split reduces outstanding shares from 15,166,596 to ~1,516,660; authorized shares from 100M to 10M.","Effective 12:01 a.m. ET on May 15, 2023; no fractional shares – any fraction rounded up.","Common stock continues trading on Nasdaq under symbol XBIO with new CUSIP 984015602.","Warrants (XBIOW) and equity awards proportionately adjusted; no action required by holders.","Press release issued May 12, 2023; Certificate of Change filed with Nevada Secretary of State."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-003243","json":"https://secwatch.observer/filing/0001683168-23-003243.json","markdown":"https://secwatch.observer/filing/0001683168-23-003243.md","text":"https://secwatch.observer/filing/0001683168-23-003243.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316823003243/0001683168-23-003243-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316823003243/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:29:09.183965+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a66a2c34d74b3be7bef749367918519981a9e07","claim":"Xenetic Biosciences, Inc.: Filed a Certificate of Change to effect a one-for-ten reverse stock split, reducing authorized common stock from 100,000,000 to 10,000,000 shares (effective 2023-05-11).","evidence_excerpt":"on May 11, 2023, Xenetic Biosciences, Inc. (the “Company”) filed a Certificate of Change to the Company’s Articles of Incorporation (the “Change”) with the Secretary of State of the State of Nevada to effect a one-for-ten reverse stock split of its authorized, issued and outstanding common stock","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534525/000168316823003243/0001683168-23-003243-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-05-11"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}